Oxford Cannabinoid Technologies pauses trigeminal neuralgia trial to ‘extend cash runway’

Oxford Cannabinoid Technologies Holdings PLC’s Clarissa Sowemimo – Coker joins Proactive to explain the rationale behind the ‘prudent’ decision to temporarily delay the phase I trial of OCT130401, the second of four programmes it is working on.

Sowemimo – Coker explains that due to the challenging market conditions currently, it made sense to extend the group’s cash runway out into the back end of next year.

Meanwhile, the first-in-human trial of the company’s lead programme, OCT461201, remains on track and on budget kicking off next January with interim results expected in April.

© 2022 Stockmark.it The Latest StockMarket News and Interviews